MCALLEN, Texas (KVEO)—Researchers at Centex Studies Inc. in McAllen are now one of nearly 100 clinics in the U.S. working to create a vaccine for COVID-19.
“In McAllen there is a strong diversity, your area fits the patient population we are looking for in the trial,” said Centex Studies Inc President, Devora Torrence.
Torrence said the clinic is actively looking for 500 people who have not tested positive for COVID-19 but have chronic diseases.
“We’re looking for frontline workers as well as high risk population. High risk could be diabetes, COPD, asthmatics, just as long as you’re 18 and above,” she added.
Half of the participants will be given the vaccine and the other half will be given a placebo. Health officials said the vaccine will only develop neutralizing antibodies not the disease itself.
“The first one is Moderna, it’s currently in the phase three process. It’s a messenger RNA vaccine,” said Torrence.
The study is focusing on minority communities as experts said that is the group getting sick the most. Torrence assured the design for this trial has been sent to the Food and Drug Administration for review.
“You get two doses of vaccines. One on day one and one on day 28 then you’re followed for about two years. There are several phone visits, in person visits that you will make during the trial to make sure you don’t have any adverse reactions and just to see how things are progressing,” she added.
If enough data is collected, officials said the vaccine could launch December or early 2021 and will continue monitoring participants to measure the length of immunity.
To participate in this study you can call (956) 540-7170 or visit www.centexstudies.com